about
Severe asthma: anti-IgE or anti-IL-5?Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.Update on optimal use of omalizumab in management of asthma.Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.Omalizumab: clinical use for the management of asthma.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsIdentifying and testing potential new anti-asthma agents.Omalizumab for the treatment of chronic urticaria.'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.The safety of monoclonal antibodies in asthma.
P2860
Q28071832-53F2BB14-8B6C-4B0B-80A7-5310FF726942Q34727734-27C32C9A-5880-4D09-A025-6ABE4208788FQ35117827-67832676-7815-4DBA-92F9-B7B3FB92D60FQ35946777-55340755-89EF-4478-BB06-5F0D10FDABC7Q36055963-D2E833B7-BAB7-4736-B7AA-DDBD8E0CA127Q36158922-525D4F77-2A5F-4187-AEB0-25E65ECA88FAQ38014555-09970CB6-A45F-43B5-B4C3-7153ACF8B797Q38310407-F3F18665-16A6-41D8-86C5-9719F4770BF7Q38661772-B900CD09-F8F9-40D1-B60C-C256440C20F7Q38842153-1422DB3E-CF7B-4796-8F87-0D8716BA3639
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety of omalizumab in asthma.
@en
Safety of omalizumab in asthma.
@nl
type
label
Safety of omalizumab in asthma.
@en
Safety of omalizumab in asthma.
@nl
prefLabel
Safety of omalizumab in asthma.
@en
Safety of omalizumab in asthma.
@nl
P2860
P1476
Safety of omalizumab in asthma.
@en
P2093
Jonathan Corren
Ricardo A Tan
P2860
P304
P356
10.1517/14740338.2011.563840
P407
P577
2011-03-15T00:00:00Z